Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Madrigal Pharmaceuticals (MDGL) over the last 6 years, with Q3 2025 value amounting to 39.68%.

  • Madrigal Pharmaceuticals' EBITDA Margin rose 1473800.0% to 39.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 41.52%, marking a year-over-year increase of 6719800.0%. This contributed to the annual value of 276.39% for FY2024, which is N/A changed from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its EBITDA Margin stood at 39.68% for Q3 2025, which was up 1473800.0% from 22.18% recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' EBITDA Margin registered a high of 22.18% during Q2 2025, and its lowest value of 1110.38% during Q2 2024.